BioSpace News Archive

Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today an oral and poster presentation at the upcoming 2023 Annual Meeting Society for Biomaterials (“SFB”), which will be held April 19th – 22nd in San Diego, CA.

Centricity Vision Inc. announced that a new study published in the Journal of Cataract & Refractive Surgery demonstrated the superiority of its Precision Pulse Capsulotomy technology over Continuous Curvilinear Capsulorhexis for capsulotomy creation in white cataracts.

AIROS® Medical, Inc., a medical technology manufacturer and designer specializing in compression therapy devices that treat lymphedema and venous complications, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market its AIROS 8P Sequential Compression Therapy device and garment system.

Dipharma Francis S.r.l. announced the completion of the expansion of its Research and Development Center for small molecules at its Headquarters located in Baranzate, close to Milan, in the North of Italy.

Baxter International Inc., a global leader in sterile medication production and delivery, announced the U.S. launch of ZOSYN Injection.

Biologica Technologies, developers and marketers of ProteiOS® growth factor and OsseoGEN® cellular bone matrix, announced two significant, separate agreements signed with Premier Inc. and Academy Medical.

Illumina Inc., a global leader in DNA sequencing and array-based technologies, announced it has already exceeded more than 200 orders for its revolutionary NovaSeq X sequencing system in the first quarter of 2023.

Waters Corporation unveiled its next generation Xevo TQ Absolute IVD mass spectrometer, expanding its family of MassTrak IVD LC-MS/MS Systems for clinical diagnostic applications.

Providence, a not-for-profit health system serving the Western U.S., and GRAIL, LLC, a healthcare company with a mission to detect cancer early when it can be cured, today announced the expansion of their partnership to offer multi-cancer early detection screening as part of clinical care to eligible individuals across the entire Providence health system.

BioHarvest Sciences (CSE: BHSC) (OTCQB: CNVCF) (the Company) is announcing that its first major 2023 product marketing campaign has launched, titled “Real Stories”